Key Developments: Daiichi Sankyo Co Ltd (4568.T)
Latest Key Developments (Source: Significant Developments)
DAIICHI SANKYO CO., LTD. Amends Consolidated Full-year Outlook for FY 2012; Affirms Year-end Dividend for FY 2012
DAIICHI SANKYO CO., LTD. announced that it has raised the consolidated full-year outlook for revenue from JPY 930,000 million to JPY 940,000 million, affirmed operating profit at JPY 100,000 million, but has lowered the consolidated full-year outlook for ordinary profit from JPY 90,000 million to JPY 77,000 million, net profit from JPY 26,000 million to JPY 15,000 million and earning per share from JPY 36.94 to JPY 21.31 for the fiscal year ending March 31, 2012. The Company has also affirmed the year-end dividend forecast at JPY 30 per share, for the fiscal year ending March 31, 2012. Full Article
DALLAS - A new blood clot and stroke preventer from Daiichi Sankyo proved as effective and safer than widely used warfarin in a large, late stage trial of patients with atrial fibrillation, paving the way for it to compete with other new warfarin alternatives on the market.